X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2263) 2263
Publication (217) 217
Book Review (41) 41
Conference Proceeding (3) 3
Dissertation (2) 2
Magazine Article (2) 2
Book Chapter (1) 1
Data Set (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1711) 1711
oncology (1338) 1338
index medicus (1324) 1324
female (1023) 1023
2nd-line treatment (977) 977
chemotherapy (878) 878
middle aged (865) 865
male (805) 805
aged (777) 777
adult (689) 689
antineoplastic combined chemotherapy protocols - therapeutic use (589) 589
cancer (580) 580
treatment outcome (565) 565
2nd-line chemotherapy (436) 436
2nd-line therapy (385) 385
antineoplastic agents - therapeutic use (357) 357
pharmacology & pharmacy (347) 347
lung neoplasms - drug therapy (346) 346
cisplatin (338) 338
open-label (336) 336
care and treatment (332) 332
double-blind (329) 329
docetaxel (312) 312
phase-ii trial (302) 302
paclitaxel (296) 296
disease-free survival (285) 285
therapy (278) 278
gemcitabine (273) 273
aged, 80 and over (270) 270
phase-iii trial (265) 265
antineoplastic combined chemotherapy protocols - adverse effects (261) 261
1st-line treatment (254) 254
carcinoma, non-small-cell lung - drug therapy (252) 252
trial (247) 247
clinical trials (241) 241
drug therapy (226) 226
research (226) 226
survival (226) 226
metastasis (220) 220
drug administration schedule (206) 206
retrospective studies (205) 205
carcinoma (203) 203
prognosis (203) 203
deoxycytidine - analogs & derivatives (199) 199
phase-ii (199) 199
survival rate (191) 191
gastroenterology & hepatology (190) 190
survival analysis (190) 190
neoplasm staging (189) 189
analysis (182) 182
medicine & public health (181) 181
combination (172) 172
supportive care (169) 169
efficacy (167) 167
neoplasm metastasis (167) 167
hematology, oncology and palliative medicine (159) 159
multicenter (158) 158
carboplatin (157) 157
2nd-line (155) 155
lung cancer (154) 154
lung neoplasms - pathology (151) 151
salvage therapy (151) 151
deoxycytidine - administration & dosage (148) 148
neoplasm recurrence, local - drug therapy (147) 147
irinotecan (145) 145
oxaliplatin (145) 145
patients (144) 144
respiratory system (144) 144
ovarian neoplasms - drug therapy (143) 143
drug therapy, combination (142) 142
bevacizumab (141) 141
cancer therapies (141) 141
1st-line therapy (140) 140
antineoplastic combined chemotherapy protocols - administration & dosage (138) 138
erlotinib (136) 136
randomized phase-iii (135) 135
antineoplastic agents (134) 134
disease progression (134) 134
randomized controlled trials as topic (134) 134
paclitaxel - administration & dosage (133) 133
drug resistance, neoplasm (131) 131
health aspects (131) 131
non-small cell lung cancer (129) 129
lung cancer, non-small cell (126) 126
mutation (124) 124
antineoplastic agents - adverse effects (122) 122
prospective studies (122) 122
antimitotic agents (121) 121
cell lung-cancer (121) 121
randomized-trial (121) 121
cancer research (118) 118
adenocarcinoma (117) 117
taxoids - administration & dosage (117) 117
adenocarcinoma - drug therapy (116) 116
review (116) 116
topotecan (116) 116
antineoplastic agents - administration & dosage (115) 115
cisplatin - administration & dosage (110) 110
dose-response relationship, drug (108) 108
helicobacter pylori (108) 108
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2209) 2209
French (29) 29
German (20) 20
Spanish (6) 6
Polish (5) 5
Japanese (3) 3
Russian (2) 2
Portuguese (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Digestion, ISSN 0012-2823, 08/2017, Volume 96, Issue 1, pp. 1 - 4
Background: Hepatocellular carcinoma (HCC) is an aggressive liver tumor with a poor 5-year survival rate. Many HCCs are not amenable to surgical resection,... 
Molecular targeted therapy | Unresectable hepatocellular carcinoma | Stereotactic body radiation therapy | Transarterial chemoembolization | Radiofrequency ablation | Checkpoint inhibition | Hepatocellular carcinoma | Hepatocellular carcinoma clinical trials | Selective internal radiotherapy with yttrium-90 | Proton beam therapy | MULTICENTER | RESECTION | PHASE-III | SORAFENIB | DOUBLE-BLIND | 2ND-LINE TREATMENT | PLACEBO-CONTROLLED TRIAL | GASTROENTEROLOGY & HEPATOLOGY | Niacinamide - analogs & derivatives | Carcinoma, Hepatocellular - mortality | Chemoembolization, Therapeutic - trends | Proton Therapy - trends | Combined Modality Therapy - trends | Humans | Radiosurgery - standards | Radiotherapy - standards | Liver Neoplasms - therapy | Liver Neoplasms - mortality | Yttrium Radioisotopes - administration & dosage | Chemoembolization, Therapeutic - methods | Combined Modality Therapy - standards | Molecular Targeted Therapy - trends | Liver Neoplasms - pathology | Radiosurgery - methods | Molecular Targeted Therapy - methods | Catheter Ablation - trends | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Survival Rate | Treatment Outcome | Clinical Trials as Topic | Tumor Burden | Proton Therapy - standards | Radiotherapy - trends | Catheter Ablation - methods | Chemoembolization, Therapeutic - standards | Radiosurgery - trends | Antineoplastic Agents, Immunological - therapeutic use | Sorafenib | Carcinoma, Hepatocellular - pathology | Radiotherapy - methods | Catheter Ablation - standards | Carcinoma, Hepatocellular - therapy | Combined Modality Therapy - methods | Proton Therapy - methods | Molecular Targeted Therapy - standards | Practice Guidelines as Topic | selective internal radiotherapy with Yttrium-90 | checkpoint inhibition | TACE | Stereotactic Body Radiation Therapy | HCC | proton beam therapy | RFA | SBRT | unresectable hepatocellular carcinoma | molecular targeted therapy | radiofrequency ablation | transarterial chemoembolization | SIRT | hepatocellular carcinoma clinical trials
Journal Article
Journal of Clinical Gastroenterology, ISSN 0192-0790, 03/2013, Volume 47, Issue 3, pp. 228 - 232
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10018, pp. 545 - 557
Summary Background Nanoliposomal irinotecan showed activity in a phase 2 study in patients with metastatic pancreatic ductal adenocarcinoma previously treated... 
Internal Medicine | PLUS GEMCITABINE | SURVIVAL | 5-FLUOROURACIL | MEDICINE, GENERAL & INTERNAL | ADENOCARCINOMA | 2ND-LINE CHEMOTHERAPY | OXALIPLATIN | PEP02 | DOCETAXEL | CARCINOMA | FOLFIRI | Leucovorin - administration & dosage | Humans | Middle Aged | Male | Fatigue - chemically induced | Diarrhea - chemically induced | Pancreatic Neoplasms - drug therapy | Neoplasm Metastasis | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Camptothecin - administration & dosage | Carcinoma, Pancreatic Ductal - mortality | Deoxycytidine - adverse effects | Female | Pancreatic Neoplasms - mortality | Neutropenia - chemically induced | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Pancreatic Ductal - drug therapy | Irinotecan | Vomiting - chemically induced | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Liposomes | Deoxycytidine - analogs & derivatives | Antimitotic agents | Medical colleges | Pancreatic cancer | Leucovorin | Product development | Research institutes | Metastasis | Antineoplastic agents | Analysis | Antigens | Chemotherapy | Medical prognosis | Clinical trials | Drug dosages | Cancer therapies | Tumors | Adenocarcinoma | Therapy | Gemcitabine | Toxicity | Evidence-based medicine | Metastases | Nanoparticles | Randomization | Motivation | Vomiting | Safety management | Toxic diseases | Neutropenia | Folinic acid | Lymphatic system | Medical treatment | Diarrhea | FDA approval | Survival | Patients | Acids | Equivalence | Interactive systems
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2007, Volume 357, Issue 4, pp. 340 - 348
Journal Article
Journal Article
Cancers, ISSN 2072-6694, 11/2018, Volume 10, Issue 11, p. 412
Systemic therapy for hepatocellular carcinoma (HCC) has changed drastically since the introduction of the molecular targeted agent sorafenib in 2007. Although... 
Systemic therapy | Molecular targeted therapy | Hepatocellular carcinoma | Immune checkpoint inhibitor | immune checkpoint inhibitor | PLACEBO | MULTICENTER | PHASE-III | systemic therapy | SORAFENIB | RAMUCIRUMAB | LENVATINIB | ONCOLOGY | DOUBLE-BLIND | TRANSARTERIAL CHEMOEMBOLIZATION | 2ND-LINE TREATMENT | molecular targeted therapy | 1ST-LINE THERAPY | hepatocellular carcinoma
Journal Article
Future Microbiology, ISSN 1746-0913, 04/2010, Volume 5, Issue 4, pp. 639 - 648
Journal Article
Journal Article